NOD-scidIl2rgtm1Wjl and NOD-Rag1nullIl2rg tm1Wjl: A model for stromal cell-tumor cell interaction for human colon cancer

Digestive Diseases and Sciences

Volumn 59, Issue 6, 2014, Pages 1169-1179

  Maykel, Justin ^a   Liu, Jian Hua ^b   Li, Hanchen ^b   Shultz, Leonard D ^c   Greiner, Dale L ^b   Houghton, JeanMarie ^b  

^a University of Massachusetts   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

Human colon cancer; Immunodeficient mouse models; NRG; NSG; Tumor stroma

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CELL GROWTH; CELL INTERACTION; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOARCHITECTURE; DRUG RESPONSE; DRUG TOLERANCE; EPITHELIUM CELL; FEMALE; FIBROBLAST; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOSIS; MOUSE; MOUSE MODEL; MOUSE STRAIN; NOD SCID GAMMA MOUSE; NOD SCID MOUSE; NONHUMAN; NRG MOUSE; PRIORITY JOURNAL; STRAIN DIFFERENCE; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; TURNOVER TIME;

AGED; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FLUOROURACIL; HOMEODOMAIN PROTEINS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; SPECIFIC PATHOGEN-FREE ORGANISMS; STROMAL CELLS;

EID: 84902244255     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3168-5     Document Type: Article

References (47)

1. Casazza A, Di Conza G, Wenes M, et al. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene. 2013;33:1743-1754.
2. Hemmings C. Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis. Pathology. 2013;45:371-381.
3. Noble P, Vyas M, Al-Attar A, et al. High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. Br J Cancer. 2013;108:2097-2105.
4. Palumbo A Jr, Ferreira LB, Reis de Souza PA, et al. Extracellular matrix secreted by reactive stroma is a main inducer of protumorigenic features on LNCaP prostate cancer cells. Cancer Lett. 2012;321:55-64.
5. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev. 2005;15:97-101. (Pubitemid 40127637)
6. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820-827. (Pubitemid 41753060)
7. Robert J. Biology of cancer metastasis. Bull Cancer. 2013;100:333-342.
8. Yu B, Chen X, Li J, et al. Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biol. 2013;14:17.
9. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-110. (Pubitemid 46067310)
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-115. (Pubitemid 46067311)
11. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111-2120. (Pubitemid 351872330)
12. Morikawa K, Walker SM, Nakajima M, et al. Influence of organ environment on the growth, selection, andmetastasis of human colon carcinoma cells in nude mice. Cancer Res. 1988;48:6863-6871. (Pubitemid 19012219)
13. Kubota T, Yamaguchi H, Watanabe M, et al. Growth of human tumor xenografts in nude mice and mice with severe combined immunodeficiency (SCID). Surg Today . 1993;23:375-377. (Pubitemid 23107579)
14. Priolo C, Agostini M, Vena N, et al. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol. 2010;176:1901-1913.
15. Tanaka Y, Wu AY, Ikekawa N, et al. Inhibition of HT-29 human colon cancer growth under the renal capsule of severe combined immunodeficient mice by an analogue of 1,25-dihydroxyvitamin D3, DD-003. Cancer Res. 1994;54:5148-5153. (Pubitemid 24313492)
16. Shultz LD, Pearson T, King M, et al. Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research. Ann N Y Acad Sci. 2007;1103:77-89. (Pubitemid 46791104)
17. Shultz LD, Brehm MA, Garcia-Martinez JV, et al. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12:786-798.
18. Li M, Zhou M, Gong M, et al. A novel animal model for bone metastasis in human lung cancer. Oncol Lett. 2012;3:802-806.
19. Simpson-Abelson MR, Sonnenberg GF, Takita H, et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol. 2008;180:7009-7018.
20. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593-598.
21. Bankert RB, Balu-Iyer SV, Odunsi K, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE. 2011;6:e24420.
22. Saito Y, Yuki H, Kuratani M, et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med. 2013;5:181ra52.
23. Agliano A, Martin-Padura I, Mancuso P, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer. 2008;123:2222-2227.
24. Cao Z, Liao L, Chen X, et al. Enhancement of antitumor activity of low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules in hepatoma 22 tumor-bearing mice. Integr Cancer Ther. 2013;12:174-181.
25. Cheng CY, Lin YH, Su CC. Anti-tumor activity of Sann-Joong-Kuey-Jian-Tang alone and in combination with 5-fluorouracil in a human colon cancer colo 205 cell xenograft model. Mol Med Rep. 2010;3:227-231.
26. Yoshioka T, Wada T, Uchida N, et al. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res . 1998;58:2583-2587. (Pubitemid 28275429)
27. Lee M, Pierce A, Mahaffey W, et al. Interleukin-2 in neoadjuvant therapy potentiates inhibitory activity of 5-fluorouracil and interferon in experimental liver metastases. Anticancer Drugs. 1994;5:239-243. (Pubitemid 24161707)
28. Ernst M, Ramsay RG. Colorectal cancer mouse models: integrating inflammation and the stroma. J Gastroenterol Hepatol. 2012;27:39-50.
29. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-337. (Pubitemid 39551661)
30. Houghton J, Li H, Fan X, et al. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev. 2010;19:1153-1166.
31. Shultz L, Goodwin N, Ishikawa F, et al. Human cancer growth and therapy in immunodeficient mouse models. In: Abate-Shen C, Politi K, Chodosh L, Olive KP, editors. Mouse models of cancer: a laboraory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013.
32. Fox JG, Ge Z, Whary MT, et al. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. Mucosal Immunol. 2011;4:22-30.
33. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;101:805-815. (Pubitemid 47040863)
34. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110:341-350. (Pubitemid 34847966)
35. Direkze NC, Hodivala-Dilke K, Jeffery R, et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004;64:8492-8495. (Pubitemid 39552057)
36. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004;101:4966-4971. (Pubitemid 38469186)
37. Worthley DL, Si Y, Quante M, et al. Bone marrow cells as precursors of the tumor stroma. Exp Cell Res . 2013;319:1650-1656.
38. Sartore-Bianchi A, Ricotta R, Cerea G, et al. Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers. 2007;22:S77-S87. (Pubitemid 46730026)
39. Demichele A, Berry DA, Zujewski J, et al. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013;19:2817-2823.
40. Martell RE, Sermer D, Getz K, et al. Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration. Oncologist. 2013;18:104-111.
41. Cho SH, Jeon J, Kim SI. Personalized medicine in breast cancer: a systematic review. J Breast Cancer. 2012;15:265-272.
42. Dammann M, Weber F. Personalized medicine: caught between hope, hype and the real world. Clinics (Sao Paulo). 2012;67:91-97.
43. Fenstermacher DA, Wenham RM, Rollison DE, et al. Implementing personalized medicine in a cancer center. Cancer J. 2011;17:528-536.
44. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, et al. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013;93:252-259.
45. Lisanti MP, Martinez-Outschoorn UE, Pavlides S, et al. Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. Cell Cycle. 2011;10:2059-2063.
46. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011;61:365-381.
47. Mi Q, Li NY, Ziraldo C, et al. Translational systems biology of inflammation: potential applications to personalized medicine. Pers Med. 2010;7:549-559.